Efficacy and safety of topical calcipotriol in management of alopecia areata: A pilot study. Issue 3 (30th January 2017)

• Record Type: Journal Article
• Authors: Narang, Tarun; Daroach, Manju; Kumaran, M. Sendhil
• Is Part Of: Dermatologic therapy. Volume 30:Issue 3(2017)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2017-01-30
• Subjects: alopecia areata -- calcipotriol -- SALT score -- vitamin D; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/dth.12464
• Languages: English
• ISSNs: 1396-0296

Abstract

Abstract: Reports have highlighted serum vitamin D deficiency and reduced 1, 25‐dihydroxyvitamin D(3) receptors(VDR) expression on hair follicles of alopecia areata(AA) patients. Very few studies have demonstrated efficacy of topical calcipotriol (vitamin D analogue) in AA. We intended to study the efficacy of calcipotriol lotion 0.005% in AA and correlate its outcome with serum vitamin D levels. We conducted a prospective study, in which 22 patients with AA were treated with calcipotriol lotion 0.005% twice daily for 3 months. Clinico‐epidemiological parameters including severity of AA and SALT score were calculated at baseline and at 12 weeks. Hair regrowth was assessed monthly at 4, 8, 12 weeks. Serum vitamin D levels were measured at baseline. After 12 weeks of treatment, hair regrowth was observed in 13 (59.1%) patients. Mean period for onset of disease stabilization and hair regrowth was 4 weeks and 4.21± 2.13 weeks, respectively. Among these 13 patients, SALT50 and SALT100 was observed in 6(46.2%) and 2(9%) patients, respectively. Response to treatment was better in patients with lower vitamin D levels ( p < .009). Topical calcipotriol can be an alternative treatment in AA and it could prove to be more useful in patients who are vitamin D deficient.